Harbin Fuerjia Technology Development Co., Ltd. agreed to acquire Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd. (SZSE:002900) for CNY 570 million on February 9, 2021. As of December 31, 2020, has total assets of CNY 3.5 million, net assets of CNY 3.5 million, operating revenue of CNY 360.3 illion, operating profit of CNY 101.7 million and net profit of CNY 76.2 million.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.12 CNY | +0.80% | -1.56% | -25.86% |
04-26 | Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023 | CI |
04-26 | Medisan Pharma's Potassium Chloride Injection Passes Drug Regulator's Evaluation | MT |
1st Jan change | Capi. | |
---|---|---|
-25.86% | 434M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- 002900 Stock
- News Harbin Medisan Pharmaceutical Co., Ltd.
- Harbin Fuerjia Technology Development Co., Ltd. agreed to acquire Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd. for CNY 570 million.